These results together manifested that SH3BGRL plays critical oncogenic function in HER2-high breast cancers, and SH3BGRL expression status is a potent biomarker to subgroup HER2-positive breast cancers and the suitable therapy strategy. This evidence concerns the gene ERBB2 and breast carcinoma.